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BACKGROUND: Multiple sclerosis (MS) is an autoim-
mune disorder, with a considerable genetic influence
on susceptibility and disease course. Cytokines play
an important role in MS pathophysiology, and genes
encoding various cytokines are logical candidates to
assess possible associations with MS susceptibility
and disease course. We previously reported an asso-
ciation of a combination of polymorphisms in the
interleukin (IL)-1B and IL-1 receptor antagonist (IL-
1RN) genes (i.e. IL-1RN allele 2 //IL-1B
3959allele
2 /) with disease severity in MS. Extending this
observation, we investigated whether IL-1b and IL-
1ra production differed depending on carriership of
this gene combination.
Methods: Twenty MS patients and 20 controls were
selected based upon carriership of the specific
combination. In whole blood, in vitro IL-1b and IL-
1ra production was determined by enzyme-linked
immunosorbent-assay after 6 and 24 h of stimulation
with lipopolysaccharide.
Results: Carriers of the specific combination pro-
duced more IL-1ra, especially in MS patients,
although not significantly. IL-1ra production was
significantly higher in individuals homozygous for
IL-1RN allele 2. In patients, Il-1ra production was
higher and IL-1b production lower compared with
controls. In primary progressive patients, the IL-1b /
IL-1ra ratio was significantly lower than in relapsing-
remitting patients.
Conclusion: Our results suggest higher in vitro IL-1ra
production in carriers of IL-1RN allele 2, with an
indication of an allelic dose
/effect relationship.
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antagonist, Multiple sclerosis, Cytokines
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Introduction
Genetics of multiple sclerosis
Multiple sclerosis (MS) is a chronic inflammatory
disease of the central nervous system with a pre-
sumed auto-immune etiology. There is a strong
genetic influence, with a concordance rate in mono-
zygotic twins of approximately 30%.
1 The genetics of
MS are thought to comprise a variety of genes,
influencing both disease susceptibility and disease
characteristics. Among these, the contribution of
genes encoding cytokines is currently under elabo-
rate investigation, as cytokines are important media-
tors in immune and inflammatory conditions, such as
multiple sclerosis. Due to the large and still increasing
number of cytokines and the complexity of their
interactions, the mechanisms by which they appar-
ently influence the outcome of disease processes are
poorly understood.
Interleukin-1 and interleukin-1 receptor
antagonist
Interleukin (IL)-1a and IL-1b are major pro-inflam-
matory cytokines, their actions being counter-regu-
lated by the naturally occurring IL-1 receptor
antagonist.
2 Several reports attribute a role to cyto-
kines of the IL-1 family in MS pathophysiology. IL-1 is
present in and around MS lesions, and might be
involved in the destruction of central nervous system
myelin.
3 Both during relapses and after interferon
treatment, elevated IL-1ra levels are present in sera of
MS patients,
4 and there is some evidence that an
increase in disease activity is followed by increased
IL-1ra serum levels.
5 Differences in either absolute
cytokine production or in the ratio of pro-inflamma-
tory and anti-inflammatory cytokines may influence
the disease course; for example, by maintaining
inflammatory activity.
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89Gene polymorphisms
In the IL-1 genes, like in several other cytokine genes,
polymorphisms have been demonstrated,
6,7 adding
an additional level of variation. Various associations
of gene polymorphisms and disease characteristics
have been published. A number of studies associate
IL-1RN allele 2 with disease severity in chronic
inflammatory conditions, such as systemic lupus
erythematosus
8 and ulcerative colitis.
9 We reported
earlier an association of a specific IL-1B
3959/IL-1RN
gene combination with disease severity in MS.
10 In
this study, carriers of a specific combination (IL-1RN
allele 2 //IL-1B
3959allele 2 /) had a significantly
higher progression rate, measured as time from
disease onset to an Expanded Disability Status Scale
score equivalent with a walking distance of 100 m.
The observed associations might be explained by
functional consequences of these gene polymorph-
isms. Assuming that cytokine production is regulated
by the polymorphism present in the encoding gene,
specific alleles might be linked to high or low
production levels. This has been demonstrated for
some polymorphisms in genes of the IL-1 fa-
mily.
6,11,12 Furthermore, it was shown very recently
that innate production of IL-1b and IL-1ra is a risk
factor for susceptibility and progression of relapse-
onset MS.
13
Study rationale
In an attempt to explain our earlier observation, we
investigated in patients and controls whether in vitro
IL-1b and IL-1ra production differed between carriers
and non-carriers of an IL-1RN /IL-1B
3959 gene
combination, previously shown to be associated
with disease severity in MS.
Methods
Study design
All subjects were unrelated Dutch white Caucasian
individuals. The study was carried out with approval
of the Medical Ethical Committee and informed
consent was obtained from all subjects. A biallelic
polymorphism at position  /3953 in the fifth exon of
the IL-1B gene
6 and a penta-allelic polymorphism in
intron 2 of the IL-1RN gene
7 had been determined for
all subjects according to previously described meth-
ods.
9 We selected from our original study population
of 148 MS patients in which we had established an
association with disease severity
10 10 patients that
were carriers of the specific combination (i.e. IL-1 RN
allele 2 //IL-1B
3959 allele 2 /) and 10 patients that
were non-carriers (IL-1RN allele 2 //IL-1B
3959 al-
lele 2 /). Carriers and non-carriers were matched for
gender, and type of disease. Each patient group
consisted of four relapsing-remitting, four secondary
progressive and two primary progressive patients.
Likewise, 20 healthy controls that were carrier (nine
controls) or non-carrier (11 controls) of the specific
combination were selected. This design defined two
subgroups of 20 subjects (patients and controls)
differing only in carriership of IL-1RN allele 2.
Subjects with exacerbations, steroid treatment, or
infections within the past 3 months were excluded
in order to avoid blood sampling in conditions that
influence cytokine production. Due to deviations of
the laboratory protocol the data of two controls were
discarded, and the results are correspondingly based
on the remaining 18 control subjects.
Whole blood stimulation
Blood was collected in two 4 ml endotoxin-free
sodium heparin tubes (Chromogenix AB, Mo ¨lndal,
Sweden) and whole blood samples were diluted 1:1
with endotoxin free RPMI 1640 (Flow Laboratories,
Rockville, MD, USA) and incubated with the appro-
priate stimuli within 60 min after sampling. The
production of cytokines was measured after stimula-
tion with Escherichia coli serotype 0111;B4 lipopo-
lysaccharide (LPS; Difco Laboratories, Detroit, MI,
USA) at a final concentration of 10 ng/ml of LPS for 6
and 24 h in 96-well tissue culture plates at 378C and
5% CO2. The supernatants were centrifuged for 10
min and stored at  /208C until assay with commer-
cially available IL-1ra and IL-1b enzyme-linked im-
munosorbent assay kits (Biosource Europe S.A.,
Fleurus, Belgium). Incubation times were chosen
on the basis of production curves generated from
preliminary data of healthy volunteers. Procedures
were performed according to the manufacturer’s
instructions. For every subject samples were run in
duplicate with and without LPS stimulation, as
control for contamination. Results are expressed in
picograms per milliliter. Whole blood was used to
maintain cell types in their in vivo ratios and to retain
all blood components. As significant relations be-
tween cytokine production in peripheral blood
mononuclear cells (PBMCs) and whole blood cul-
tures have recently been reported,
14 comparisons
with studies using peripheral blood mononuclear
cells can be reliably made.
Statistical analysis
Production levels between groups and within groups
were analyzed using one-way/two-way analysis of
variance, Mann/Whitney and Kruskal/Wallis tests.
Correlations were calculated using Spearman’s rank
correlation test. Significance levels were set at 5%
(two sided, p/0.05), and p B/0.10 was considered a
trend.
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Relevant features of patients and controls are sum-
marized in Table 1. Baseline levels (without stimula-
tion) were all below 300 pg/ml. Average cytokine
levels after LPS stimulation in patients and controls
are shown in Figs. 1 and 2. Cytokine levels after 6 and
24 h correlated significantly (p B/0.01) for both IL-1ra
(r/0.83) and IL-1b (r/0.90).
IL-1ra production
IL-1ra production was considerably higher in IL-1RN
allele 2 carriers (MS and controls combined) than in
non-carriers after 6 and 24 h (Fig. 1; 24% and 21%,
respectively), although not significant (p/0.16 and
p/0.25). IL-1ra production was similar in MS
patients and controls after 6 h, but considerably
higher (18%) after 24 h stimulation (p/0.303). The
higher production in MS patients was due to elevated
levels (36%) in the IL-1RN allele 2 //IL-1B
3959 allele
2 / group. Although IL-1ra levels after 6 h were 16%
higher in IL-1RN allele 2 //IL-1B
3959 allele 2 /
controls, 24 h levels did not differ between IL-1RN
allele 2 carriers and non-carriers (Fig. 2). The
observed differences were not statistically significant.
There was a trend (p/0.095) towards higher pro-
duction in controls and patients homozygous for IL-
1RN allele 2 after 6 h, and a significant difference
after 24 h (Fig. 3; p/0.043). Gender, age and disease
type did not influence cytokine production signifi-
cantly.
IL-1b production
A trend towards higher IL-1b production in controls
compared with patients after 6 h (32%) and 24 h
(27%) stimulation was observed (p/0.80 and p/
0.094). Also, a trend in primary progressive patients
to produce less IL-1b after 24 h than relapsing-
remitting or secondary progressive patients was
seen (44%; p/0.059). No significant differences
were observed with regard to genotype, age or
gender.
IL-1b /IL-1ra ratio
Assuming that a higher IL-1b/IL-1ra ratio reflects
enhanced pro-inflammatory activity, this ratio was
calculated from the cytokine production levels. No
significant differences were observed with regard to
genotype or gender. A significantly lower IL-1b/IL-1ra
ratio was observed in primary progressive patients
compared with relapsing remitting patients, with a
ratio of 0.37 versus 1.14 after 6 h (p/0.038) and of
0.17 versus 0.45 after 24 h (p/0.017; Table 2). Both
higher IL-1ra levels and lower IL-1b levels in the
primary progressive patients underlie the observed
difference.
Discussion
In 1999 we established an association of a specific
combination of polymorphisms in the IL-1B and IL-
1RN genes (i.e. IL-1RN allele 2 //IL-1B
3959allele
2 /) with disease severity in MS.
10 Although a large
study in the UK did not show any evidence in favor of
a role for the IL-1RN gene in susceptibility to MS or its
progression,
15 other reports provided support for our
original observation that polymorphisms in the IL-1
gene cluster are associated with disease severity.
16,17
Furthermore, the production of IL-1ra and IL-1b has
very recently been proposed as a risk factor for
susceptibility and progression of relapse-onset MS.
13
Hence, in an effort to explain our observed associa-
tion, this study addresses whether a specific genetic
make-up of the IL-1 genes is reflected in cytokine
production. Although other studies have shown that
inter-individual cytokine production is highly vari-
able, intra-individual production is remarkably stable
over time and appears to be characteristic of an
individual.
11,14 In addition, we tried to limit influence
of disease activity on cytokine production by blood
sampling in periods without recent exacerbations. In
favor of an effect on cytokine production is our
observation that IL-1RN allele 2 carriers produced
more IL-1ra than IL-1RN allele 2 non-carriers, as was
anticipated from available data.
11,18 Furthermore,
there was in individuals (patients and controls)
homozygous for IL-1RN allele 2 a consistent trend
Table 1. Characteristics of MS patients and controls
MS patients (n/20) Controls (n/18)
IL-1RN 2 //IL-1B
3959 2 / IL-1RN 2 //IL-1B
3959 2 / IL-1RN 2 //IL-1B
3959 2 / IL-1RN 2 //IL-1B
3959 2 /
Female 3 3 3 6
Male 7 7 4 5
Age9 /SD (years) 43.49 /12.7 49.39 /15.3 30.99 /5.2 37.89 /9.5
RR 4 (3 M, 1 F) 4 (3 M, 1 F)
SP 4 (3 M, 1 F) 4 (3 M, 1 F) Not applicable Not applicable
PP 2 (1 M, 1 F) 2 (1 M, 1 F)
RR, Relapsing-remitting; SP, secondary progressive; PP, primary progressive; SD, standard deviation; M, male; F, female.
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implies an allelic dose/effect relationship with re-
gard to cytokine production, and is in line with an
Italian study that showed that peripheral blood
mononuclear cells from healthy controls homozy-
gous for IL-1RN allele 2 produce significantly more
IL-1ra.
19
Unfortunately, due to the rarity of patients that are
homozygous for IL-1RN allele 2 and non-carriers of
IL-1B
3959 allele 2, we were not able to further
explore this observation in the present study. Despite
the mentioned raised IL-1ra levels in IL-1RN allele 2
carriers, the observed differences between carriers
and non-carriers of IL-1RN allele 2 did not reach
statistical significance. Obviously, this argues against
a major influence of the studied gene combination on
cytokine production. What, then, to conclude from
this and earlier research? First, it should be noted that
the size of this exploratory study may hamper
detection of differences in production levels. Second,
it has been shown that IL-1ra production is not only
determined by the IL-1RN gene polymorphisms, but
is co-regulated by the IL-1B
3959 polymorphism.
12
Given the specific gene combination that we inves-
tigated, all individuals are IL-1B
3959 allele 1 homo-
zygous, and hence the observed differences in IL-1b
FIG. 1. IL-1ra and IL-1b levels after 6 and 24 h in carriers(IL-1RN allele 2 //IL-1B
3959allele 2 /) and non-carriers (IL-1RN allele
2 //IL-1B
3959allele 2 /) of IL-1RN allele 2.
FIG. 2. Mean IL-1ra and IL-1b levels after 6 and 24 h in MS patients and controls (HC) after stratiﬁcation for IL-1RN allele 2
carriership. 2 /, IL-1RN allele 2 //IL-1b allele 2 /;2  /, IL-1RN allele 2 //IL-1b allele 2 /.
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gene polymorphism. In a recent report, despite
significant differences in IL-1b and IL-1ra production
levels between families of MS patients, no associa-
tions with IL-1B and IL-RN gene polymorphisms
were established, leading the authors to suggest that
possibly other polymorphisms are responsible for the
differences they observed.
13
As a separate observation, unrelated to the gene
polymorphisms, we found in primary progressive
patients a trend towards lower production of IL-1b
and significantly lower IL-1b/IL-1ra ratios (after 6 and
24 h) than in relapsing-remitting patients. This is
consistent with the current opinion that in primary
progressive patients inflammation is a less prominent
feature.
20 Since only four primary progressive pa-
tients were included, our findings must of course be
interpreted with caution.
In short, the findings of this study cannot be
viewed, nor are they presented, as conclusive. They
do suggest, however, higher IL-1ra production in
carriers of the IL-1RN allele 2, with a possible allelic
dose/effect relationship. Furthermore, the IL-1RN
gene polymorphism might not be the only determi-
nant of IL-1ra production, but other factors that could
well be other gene polymorphisms are probably also
involved. Larger studies combining clinical, genetic,
and functional data (both in vitro and in vivo) are
needed to obtain definite answers concerning the
role of cytokine genes like those of the IL-1 gene
cluster in MS and other diseases.
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